Monopar Therapeutics

MNPR

Exchange: Nasdaq
Industry: Pharmaceutical Preparations
SEC CIK: 0001645469

SEC filings (opens in a new tab)

In the last 90 days, Monopar Therapeutics insiders filed 0 open-market purchases and 4 sales; 95 institutions reported holding it in 13F filings for Q2 2026, worth $576.1M in total; no superinvestor holds it.

Q2 2021 vs. Q1 2021

How the institutions holding Monopar Therapeutics changed between Q1 2021 and Q2 2021.

All holders in Q2 2021 All holders in Q1 2021

13F holders of MNPR: Q1 2021 compared with Q2 2021
Measure	Q1 2021	Q2 2021	Change
Holders	13	10	−3
Shares	194.8K	187.5K	−7.37K (−3.8%)
Value	$1.21M	$1.10M	−$103.2K (−8.5%)

New holders (1)

Institutions that held Monopar Therapeutics at the end of Q2 2021 but not at the end of Q1 2021.

Institutions new to MNPR in Q2 2021
Institution	Shares	Value	% of portfolio
Paragon Wealth Strategies, LLC	58	$0	0.00%

Sold out (4)

Institutions that held Monopar Therapeutics at the end of Q1 2021 and filed for Q2 2021 without it.

Institutions that sold out of MNPR in Q2 2021
Institution	Shares, Q1 2021	Value, Q1 2021
Marshall Wace, LLP	47,653	$295.0K
Citadel Advisors LLC	12,479	$77.0K
Tower Research Capital LLC (TRC)	2,212	$14.0K
UBS Group AG	571	$4.00K